This bioavailable estrogen could result in increased ER activation, metabolic switching to an alternative estrogen metabolic pathway, or imbalance of the estrogen/progesterone ratio that has been implicated in other tumor types (mammary, prostate) (Lai et al., 2015). The gene discussed is ESR1; the disease is neoplasm.